Economic evaluation of human papillomavirus vaccination in the United Kingdom


Jit, M; Choi, YH; Edmunds, WJ; (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ, 337. a769. ISSN 0959-535X DOI: 10.1136/bmj.a769

[img]
Preview
Text - Published Version
License:

Download (174Kb) | Preview

Abstract

OBJECTIVE: To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls against human papillomavirus infection in the United Kingdom. DESIGN: Economic evaluation. SETTING: UK. Population Schoolgirls aged 12 or older. MAIN OUTCOME MEASURES: Costs, quality adjusted life years (QALYs), and incremental cost effectiveness ratios for a range of vaccination options. RESULTS: Vaccinating 12 year old schoolgirls with a quadrivalent vaccine at 80% coverage is likely to be cost effective at a willingness to pay threshold of pound30,000 (euro37,700; $59,163) per QALY gained, if the average duration of protection from the vaccine is more than 10 years. Implementing a catch-up campaign of girls up to age 18 is likely to be cost effective. Vaccination of boys is unlikely to be cost effective. A bivalent vaccine with the same efficacy against human papillomavirus types 16 and 18 costing pound13- pound21 less per dose (depending on the duration of vaccine protection) may be as cost effective as the quadrivalent vaccine although less effective as it does not prevent anogenital warts. CONCLUSIONS: Routine vaccination of 12 year old schoolgirls combined with an initial catch-up campaign up to age 18 is likely to be cost effective in the UK. The results are robust to uncertainty in many parameters and processes. A key influential variable is the duration of vaccine protection.

Item Type: Article
Keywords: Adolescent, Age Distribution, Child, Colposcopy/economics, Condylomata Acuminata/economics/prevention & control, Cost-Benefit Analysis, Female, Great Britain, Humans, Male, Mass Screening/economics, Papillomavirus Infections/economics/*prevention & control, Papillomavirus Vaccines/*economics, Patient Satisfaction, Quality-Adjusted Life Years, Regression Analysis, Uterine Cervical Neoplasms/economics/*prevention & control/virology, Vaccination/*economics, Adolescent, Age Distribution, Child, Colposcopy, economics, Condylomata Acuminata, economics, prevention & control, Cost-Benefit Analysis, Female, Great Britain, Humans, Male, Mass Screening, economics, Papillomavirus Infections, economics, prevention & control, Papillomavirus Vaccines, economics, Patient Satisfaction, Quality-Adjusted Life Years, Regression Analysis, Uterine Cervical Neoplasms, economics, prevention & control, virology, Vaccination, economics, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin, AdolescentAge DistributionChildColposcopy/economicsCondylomata Acuminata/economics/prevention & controlCost-Benefit AnalysisFemaleGreat BritainHumansMaleMass Screening/economicsPapillomavirus Infections/economics/*prevention & controlPapillomavirus Vaccin
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Vaccine Centre
PubMed ID: 18640957
Web of Science ID: 258561100031
URI: http://researchonline.lshtm.ac.uk/id/eprint/6834

Statistics


Download activity - last 12 months
Downloads since deposit
403Downloads
344Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item